Infinity Announces Phase I Data from IPI-145 Against R/R Lymphomas

At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Infinity Pharmaceuticals announced updated Phase 1 data from an ongoing study of IPI-145, the company's potent oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients diagnosed with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma as well as Hodgkin's lymphoma.

Call

Preliminary data indicates that IPI-145 is both well-tolerated and clinically active in patients with subtypes including some indolent non-Hodgkin's lymphomas, T-cell lymphoma, mantle cell lymphoma (MCL) and Hodgkin's lymphoma (HL).

Said trial investigator Steven Horwitz, MD, assistant attending physician in the department of medicine at the Memorial Sloan-Kettering Cancer Center:

I’m encouraged by the early data seen in this Phase 1 study of IPI-145. So far, IPI-145 appears to be well tolerated, with responses seen across a broad range of B-cell and T-cell lymphomas. Many hematologic malignancies are difficult to treat and new agents are clearly needed. Targeted therapies, including IPI-145, have the potential not only to add therapeutic options for our patients but also to reduce or delay the need for chemotherapy, possibly changing the way many of these malignancies are treated.

It wasn't Infinity's only presentation. The company also announced that that its Phase 2 study of IPI-145 in hematologic malignancies is open for enrollment. This trial will be a Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of IPI-145. They are looking to enroll 120 patients with refractory indolent non-Hodgkin's lymphomas, since data from the Phase 1 study showed that 13 of 19 patients with indolent NHLs had responses to IPI-145, including three who had complete responses.

Said Julian Adams, PhD, president of research and development at Infinity:

Infinity is pleased to begin its first Phase 2 study of IPI-145 in patients with indolent non-Hodgkin lymphoma, which is supported by the early, encouraging, data from our ongoing Phase 1 study reported today at ASCO. Infinity believes IPI-145 has the potential to be the best-in-class PI3K inhibitor for the treatment of blood cancers, and we are rapidly advancing IPI-145 in the clinic with a goal of addressing significant medical needs.

Source: ASCO '13

Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...